US2015284340A1PendingUtilityA1
Quinazoline based egfr inhibitors containing a zinc binding moiety
Est. expirySep 11, 2026(~0.1 yrs left)· nominal 20-yr term from priority
A61P 35/04C07D 239/94C07D 403/12C07D 405/04C07D 401/12C07D 405/12A61P 43/00C07D 409/12A61P 35/00A61P 35/02C07D 239/93C07D 239/88A61K 31/517
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (IV) below: These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
Claims
exact text as granted — not AI-modified1 - 14 . (canceled)
15 . A compound of the formula
or a salt thereof, wherein A is selected from the group consisting of
16 . The compound of claim 15 , wherein A is
17 . The compound of claim 15 , wherein A is
18 . A method of producing a compound of Formula XX
comprising the step of reacting a compound of the formula
with hydroxylamine, thereby producing the compound of Formula XX, wherein A is selected from the group consisting of
19 . The method of claim 18 , wherein A is
20 . The method of claim 18 , wherein A isJoin the waitlist — get patent alerts
Track US2015284340A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.